Drugs that in some reports have been associated with torsades de pointes and/or QT prolongation but at this time lack substantial evidence for causing torsades de pointes.
Class/Clinical Use Comments
Diuretic / stimulate urine & salt loss
Revised: 01/29/2010 Printed: 02/02/2010 Source: www.QTdrugs.org
Drugs on the QT Drug Lists are reviewed on an ongoing basis to assure the evidence is still appropriate for their placement on their respective list.
Arizona Center for Education and Research on Therapeutics The Critical Path Institute Tucson, Arizona and Rockville, Maryland
Funded in part by Agency for Healthcare Research and Quality grant 1 U18 HS10385
Disclaimer and Waiver The information presented is intended solely for the purpose of providing general information about health related matters. It is not intended for any other purpose, including, but not limited to, medical or pharmaceutical advice and/or treatment, nor is it intended to substitute for the users' relationships with their own health care/pharmaceutical providers. To that extent, by continued use of this program, the user affirms the understanding of the purpose and releases The Critical Path Institute, The University of Arizona, State of Arizona and Arizona Board of Regents from any claims arising out of his/her use of the website.
Drugs that are generally accepted by the QTdrugs.org Advisory Board of the Arizona CERT to have a risk of causing torsades de pointes.
Class/Clinical Use Comments
Revised: 03/25/2008 Printed: 02/02/2010 Source: www.QTdrugs.org
Drugs on the QT Drug Lists are reviewed on an ongoing basis to assure the evidence is still appropriate for their placement on their respective list.
Females > Males: Substantial evidence indicates a greater risk (usually > two-fold) of TdP in women Arizona Center for Education and Research on Therapeutics The Critical Path Institute Tucson, Arizona and Rockville, Maryland
Funded in part by Agency for Healthcare Research and Quality grant 1 U18 HS10385
Disclaimer and Waiver The information presented is intended solely for the purpose of providing general information about health related matters. It is not intended for any other purpose, including, but not limited to, medical or pharmaceutical advice and/or treatment, nor is it intended to substitute for the users' relationships with their own health care/pharmaceutical providers. To that extent, by continued use of this program, the user affirms the understanding of the purpose and releases The Critical Path Institute, The University of Arizona, State of Arizona and Arizona Board of Regents from any claims arising out of his/her use of the website.
Venue Azia Resort and Spa, Paphos, Cyprus Official Rating: 5* General Information: Built as three different sections on adjacent grounds, with plethora of magnificent spaces for carefree living, the Azia Resort has all the diversity to keep its guests contented for a week or longer. Each element of the three-in-one boutique Cyprus hotel concept has its own c
The report goes on to say that chiropractors “allied themselves with the Red Cross initially in order to maintain access to the facility, but they were able to offer The April 19, 2004 issue of the Journal of a specific skill, which even if not planned for in advance, Vertebral Subluxation Research provides us with an seemed useful to those who already had access.” interesting artic
Drugs that in some reports have been associated with torsades de pointes and/or QT prolongation but at this time lack substantial evidence for causing torsades de pointes.
Class/Clinical Use 
Revised: 01/29/2010 Printed: 02/02/2010 Source: www.QTdrugs.org
Drugs on the QT Drug Lists are reviewed on an ongoing basis to assure the evidence is still appropriate for their placement on their respective list.
Arizona Center for Education and Research on Therapeutics 
Drugs that are generally accepted by the QTdrugs.org Advisory Board of the Arizona CERT to have a risk of causing torsades de pointes.
Class/Clinical Use 
Revised: 03/25/2008 Printed: 02/02/2010 Source: www.QTdrugs.org
Drugs on the QT Drug Lists are reviewed on an ongoing basis to assure the evidence is still appropriate for their placement on their respective list.
Females > Males: Substantial evidence indicates a greater risk (usually > two-fold) of TdP in women